21 October 2022: Articles
Brain Abscesses Caused by in a 44-Year Old Woman with Multiple Myeloma: A Rare Case and Review of the Literature
Challenging differential diagnosis, Diagnostic / therapeutic accidents, Management of emergency care, Rare disease, Rare coexistence of disease or pathology
Khalid Sayer A , Yousef A.I. Abousedu A , Omar M. Ghanem A , Muhammad Doghaim A , Faisal Sayer A*DOI: 10.12659/AJCR.937952
Am J Case Rep 2022; 23:e937952
Table 2. Summary of previously published case reports of cerebral nocardiosis in patients with multiple myeloma.
| Author, year of study | Age/Sex | Chemotherapy regimen | Clinical presentation | Nocardia species | Treatment | Outcome |
|---|---|---|---|---|---|---|
| Monticelli J et al, 2015 []3 | 70/M | /Prednisone/; followed by /Dexamethsone | Seizures | TMP-SMX plus meropenem; followed by ciprofloxacin | Survived | |
| Pamukçuoğlu M et al, 2014 []4 | 61/F | Cyclophosphamide, and Dexamethasone | Seizures | Surgical excision; meropenem followed by amoxacillin-clavulanic acid | Survived | |
| Pamukçuoğlu M et al, 2014 []4 | 60/F | Cyclophosphamide, and Dexamethasone | Dysarthria and gait disturbances | Surgical excision; imipenem/cilastatin followed by TMP-SMX | Survived | |
| AlSamman S et al, 2014 []6 | 64/M | Seizures | Ceftriaxone plus TMP-SMX | Survived | ||
| Matin A t al, 2017 []8 | 68/F | , , Thalidomide, Adriamycin, Cyclophosphamide, Cisplatin and Etoposide | Right sided facial palsy with right sided hemiplegia | Surgical debridement; TMP-SMX, Linezolid and Imipenem followed by TMP-SMX plus Tedizolid | Survived | |
| Xu N et al, 2021 []7 | 69/F | , , Dexamethasone and Cyclophosphamide | Convulsion of the limbs with left-sided hemiplegia | TMP-SMX plus Ceftriaxone followed by TMP-SMX plus Moxifloxacin | Survived | |
| Our Case | 44/F | Cyclophosphamide, thalidomide and Dexamethasone | Seizures | Surgical excision; Meropenem, Amikacin and TMP-SMX followed by TMP-SMX | Survived | |
| M – male; F – female; TMP-SMX – Trimethoprim-Sulfamethoxazole. Novel therapeutic multiple myeloma agents are highlighted in | ||||||